Skip to main content

Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis

    Basic Details
    Date Posted
    Medical Product
    Health Outcome(s)
    renal cell carcinoma

    In this analysis, we examined counts of individuals with type 2 diabetes initiating canagliflozin or comparators in the Sentinel Distributed Database (SDD), and captured available follow-up time, days supplied, and renal cell carcinoma events among these individuals.

    We conducted this analysis in two separate runs with different study periods. The first run includes data from March 29, 2013 to October 31, 2021. The second run includes data from October 1, 2015 to October 31, 2021. We distributed this request to seven Sentinel Data Partners on June 10, 2022.

    Additional Details
    FDA Center
    Time Period
    March 29, 2013 - October 31, 2021
    Analysis Type
    Population / Cohort
    Individuals 18 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)